Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
454
datasets available to search
ShareScore release 0.9.0
Dataset results
454 results for “preclinical”
Dataset related to "Translational approach to assess brain injury after cardiac arrest in preclinical models: a narrative review"
Open the record for dataset details and reuse information.
Data from: Non-industry sponsored preclinical studies on statins yield greater efficacy estimates than industry-sponsored studies: a meta-analysis
Industry-sponsored clinical drug studies are associated with publication of outcomes that favor the sponsor, even when controlling for potential bias in the methods used. However, the influence of sponsorship bias has not been examined in preclinical animal studies. We performed a meta-analysis of preclinical statin studies to determine whether industry sponsorship is associated with either increased effect sizes of efficacy outcomes and / or risks of bias in a cohort of published preclinical statin studies. We searched Medline (January 1966 - April 2012) and identified 63 studies evaluating the effects of statins on atherosclerosis outcomes in animals. Two coders independently extracted study design criteria aimed at reducing bias, results for all relevant outcomes, sponsorship source, and investigator financial ties. The I2 statistic was used to examine heterogeneity. We calculated the standardized mean difference (SMD) for each outcome and pooled data across studies to estimate the pooled average SMD using random effects models. In a priori subgroup analyses, we assessed statin efficacy by outcome measured, sponsorship source, presence or absence of financial conflict information, use of an optimal time window for outcome assessment, accounting for all animals, inclusion criteria, blinding, and randomization. The effect of statins was significantly larger for studies sponsored by non-industry sources (-1.99; 95% CI -2.68, -1.31) versus studies sponsored by industry (-0.73; 95% CI -1.00, -0.47) (p value < 0.001). Statin efficacy did not differ by disclosure of financial conflict information, use of an optimal time window for outcome assessment, accounting for all animals, inclusion criteria, blinding, and randomization. Possible reasons for the differences between non-industry and industry sponsored studies, such as selective reporting of outcomes, require further study.
Development of preclinical diagnostic tools of hepatobiliary tumors associated with Opisthorchis felineus infection in population of endemic regions
<p>According to the official medical statistics, the incidence of hepatobiliary tumors (including cholangiocarcinoma) in the Tomsk region was 9.31 cases per 100,000 population in 2011-2013, which was twice the average in Russia [Fedorova OS, Kovshirina Yu.V., et al., 2017]. Cholangiocarcinoma is a group of intra- and / or extrahepatic bile ducts cancer with high mortality due to its aggressiveness, lack of specific symptoms and / or prolonged asymptomatic course and resistance to therapy [Bridgewater J, Galle PR, Khan SA et al., 2014]. One of the significant risk factors for liver cancer is the high prevalence of parasitic infection caused by liver fluke O. felineus in Western Siberia, whose carcinogenic potential has been demonstrated in a number of experimental studies in animal models of the disease, as well as in research on autopsy material, surgical data [Gouveia MJ, Pakharukova MY, et al., 2017; Brazhnikov N.A. et al., 2002; Maksimova GA, Pakharukova MY, 2017; Bychkov V.G., 2003; Kovshirina YV, Fedorova OS, Kovshirina AE et al, in press, 2018]. In this regard, it is necessary to develop diagnostic tools allowed timely detection of severe hepatobiliary diseases (including cancer) associated with opisthorchiasis in order to jugulate it and improve the prognosis for patients in endemic regions. In this way, the aim of this project is creation a diagnostic tools for early preclinical diagnostics of the hepatobiliary tumors (cholangiocarcinoma) in patients with chronic O. felineus infection in endemic regions. For these aims a comprehensive fundamental research will be performed, including evaluation of biochemical measures (lactate, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, alkaline phosphatase, glucose, direct and indirect bilirubin, high and low density lipoproteins, triacylglycers, as well as low-density lipotropes. Immunological parameters (TGFb) and tumor markers (CA 19-9, СYFRA 21-1) in serum samples obtained from patients with O. felineus infection having periductal fibrosis and without it, patients with cholangiocarcinoma and individuals without opisthorchiasis and bile ducts cancer. Statistical analysis was carried out using the programming language R version 3.6.1. The study results indicate that ultrasound of the liver and biliary system with the assessment of opistorchosis-associated periductal fibrosis together with the determination of biochemical indicators (alkaline phosphatase, direct bilirubin, AST, glucose), as well as oncomarker CA 19-9, as predictors of fibrosis, can be used as an algorithm for early preclinical diagnosis of malignant tumors of the hepatobiliary system (cholangiocarcinoma) against the background of chronic infection O. felineus, in the population of endemic regions.</p>
Figure 1 from: Pavliuk B, Stechyshyn I, Chubka M, Hroshovyi T (2021) Preclinical safety evaluation of drone brood homogenate and justification of pharmacological action. Pharmacia 68(4): 771-777. https://doi.org/10.3897/pharmacia.68.e70678
Figure 1 Relationships between metabolic syndrome, insulin resistance, pre-diabetes and type 2 diabetes mellitus.
Synthesis and preclinical evaluation of a novel fluorine-18 labeled small-molecule PET radiotracer for imaging of CXCR3 receptor in mouse models of atherosclerosis
<p>Background CXCR3 is a chemokine receptor and is expressed in innate and adaptive immune cells. It promotes<br> the recruitment of T-lymphocytes and other immune cells to the inflammatory site in response to the binding of cognate<br> chemokines. Upregulation of CXCR3 and its chemokines has been found during atherosclerotic lesion formation.<br> Therefore, detection of CXCR3 by positron emission tomography (PET) radiotracer can be a useful tool for detecting the development of atherosclerosis in a noninvasive manner. Herein, we report the synthesis, radiosynthesis, and characterization of a novel fluorine-18 (F-18, <sup>18</sup>F) labeled small-molecule radiotracer for the imaging of the CXCR3 receptor in mouse models of atherosclerosis.<br> Results The reference standard <strong>1</strong> and its precursor <strong>9</strong> were synthesized over 5 steps from starting materials in good to moderate yields. The measured K<sub>i</sub> values of CXCR3A and CXCR3B were 0.81 ± 0.02 nM and 0.31 ± 0.02 nM, respectively. [<sup>18</sup>F]<strong>1</strong> was prepared by a two-step radiosynthesis with a decay-corrected radiochemical yield of 13 ± 2%, radiochemical purity > 99%, and specific activity of 44.4 ± 3.7 GBq/μmol at the end of synthesis (n = 6). The baseline studies showed that [<sup>18</sup>F]<strong>1</strong> displayed high uptake in the atherosclerotic aorta and brown adipose tissue in Apolipoprotein E (ApoE) knockout (KO) mice fed with a high-fat diet over 12 weeks. The uptake of [<sup>18</sup>F]<strong>1</strong> in these regions was reduced significantly in self-blocking studies, demonstrating CXCR3 binding specificity. Contrary to this, no significant differences in uptake of [<sup>18</sup>F]<strong>1</strong> in the abdominal aorta of C57BL/6 control mice fed with a normal diet were observed in both baseline and blocking studies, indicating increased CXCR3 expression in atherosclerotic lesions. Immunohistochemistry studies demonstrated that [<sup>18</sup>F]<strong>1</strong>-positive regions were correlated with CXCR3 expression, but some<br> atherosclerotic plaques with significant size were not detected by [<sup>18</sup>F]<strong>1</strong>, and their CXCR3 expressions were minimal.<br> Conclusion [<sup>18</sup>F]<strong>1</strong> was synthesized with good radiochemical yield and high radiochemical purity. In PET imaging<br> studies, [<sup>18</sup>F]<strong>1</strong> displayed CXCR3-specific uptake in the atherosclerotic aorta in ApoE KO mice. [<sup>18</sup>F]<strong>1</strong> visualized CXCR3<br> expression in different regions in mice aligned with the tissue histology studies. Taken together, [<sup>18</sup>F]<strong>1</strong> is a potential<br> PET radiotracer for imaging CXCR3 in atherosclerosis.</p>
Evaluation of Preclinical Toxicity andTherapeutic Efficacy of Kandhaga Rasayanam in Padarthamarai
ClinicalTrials.gov study NCT02238912. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosoma
ClinicalTrials.gov study NCT03977584. IPD Sharing: YES. Countries: 1. Publications: 0.
Neurobehavioral Signatures of Sign- and Goal-Tracking in Emerging Adults: Translation of a Preclinical Model
ClinicalTrials.gov study NCT07094061. IPD Sharing: YES. Countries: 1. Publications: 0.
Data from: The relationship between risk of bias criteria, research outcomes, and study sponsorship in a cohort of preclinical thiazolidinedione animal studies: a meta-analysis
Open the record for dataset details and reuse information.
Data from: Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk/benefit to patients.
Open the record for dataset details and reuse information.
Data from: Non-industry sponsored preclinical studies on statins yield greater efficacy estimates than industry-sponsored studies: a meta-analysis
Open the record for dataset details and reuse information.
Data from: Evolution of ischemic damage and behavioural deficit over 6 months after MCAo in the rat: selecting the optimal outcomes and statistical power for multi-centre preclinical trials
Open the record for dataset details and reuse information.
Data from: White matter hyperintensities and CSF AD biomarkers in preclinical Alzheimer’s disease
Open the record for dataset details and reuse information.
Association of CSF biomarkers with hippocampal-dependent memory in preclinical Alzheimer disease
Open the record for dataset details and reuse information.
CSF synaptic biomarkers in the preclinical stage of Alzheimer’s disease and their association with MRI and PET markers of neurodegeneration: a cross-sectional study
Open the record for dataset details and reuse information.
Impact of Maternal Immune Activation and Sex on Placental and Fetal Brain Cytokine and Gene Expression Profiles in a Preclinical Model of Neurodevelopmental Disorders
GEO Series GSE248222. Mus musculus. 64 samples. Type: Expression profiling by high throughput sequencing.
Improving anti–CTLA-4 therapies through peptide masking and fragment crystallizable nonfucosylation: preclinical characterization of three novel antibodies
GEO Series GSE315417. Mus musculus. 105 samples. Type: Other.
A first-in-class, humanized antibody targeting alternatively spliced tissue factor: preclinical evaluation in an orthotopic model of pancreatic ductal adenocarcinoma
GEO Series GSE158847. Homo sapiens. 9 samples. Type: Expression profiling by high throughput sequencing.
CDK12/13 inactivation triggers STING-mediated antitumor immunity in preclinical models [RNA-seq]
GEO Series GSE283088. Mus musculus. 12 samples. Type: Expression profiling by high throughput sequencing.
An in vivo avian paradigm to model human melanoma disease and perform fast and relevant preclinical studies
GEO Series GSE206689. Homo sapiens. 4 samples. Type: Expression profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.